The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Scott T. Tagawa
Consultant or Advisory Role - Janssen; Sanofi
Honoraria - Janssen; Sanofi
Research Funding - Janssen; Sanofi
Edwin M. Posadas
No relevant relationships to disclose
Justine Yang Bruce
No relevant relationships to disclose
Emerson A. Lim
No relevant relationships to disclose
Daniel Peter Petrylak
Honoraria - Johnson & Johnson
Research Funding - Johnson & Johnson
Weimin Peng
Employment or Leadership Position - Janssen Research & Development
Raymond Scott Maul
Employment or Leadership Position - Janssen Research & Development
Hans W. Smit
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Namphuong Tran
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
David M. Nanus
No relevant relationships to disclose